live Pashinyan's party is poised to win, but parliamentary seat count remains uncertain
Armenian Prime Minister Nikol Pashinyan's party is on course for victory, with Armenian media reporting that the country's Central Election Commission...
French pharmaceutical giant Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines for $9.1 billion to strengthen its portfolio in rare immunological diseases.
France-based pharmaceutical company Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines Corporation for $9.1 billion, in a strategic move to bolster its presence in rare immunological diseases.
Blueprint, a biopharmaceutical company specializing in systemic mastocytosis (SM) and other KIT-driven diseases, accepted Sanofi’s offer of $129 per share in cash. The offer represents a 27% premium over Blueprint’s last closing price of $101.35 on Friday.
The acquisition includes Ayvakit (avapritinib), a treatment for SM approved in both the U.S. and EU, along with a robust early- and late-stage immunology pipeline.
“Blueprint’s established relationships with allergists, dermatologists, and immunologists are expected to enhance Sanofi’s growing immunology portfolio,” the French company said in a statement.
The transaction is expected to close in the third quarter of 2025, pending regulatory approvals.
As part of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR), entitling them to potential milestone payments of $2 and $4 per CVR based on future achievements.
Blueprint is currently the only company with an approved drug for systemic mastocytosis - a rare disorder caused by excess mast cells - and is also developing next-generation therapies for SM and other immune disorders.
The acquisition marks the largest healthcare M&A deal in Europe so far this year. It follows Sanofi’s recent purchase of Vigil Neuroscience for $470 million last month - the second time the French company has acquired Vigil in 2025, after an initial purchase in January.
Counting is underway in Armenia's elections. The results of the vote are set to determine the political direction of the country of three million people for the next few years. Prime Minister Nikol Pashinyan is hoping to fend off challenges from several pro-Russia candidates to secure a third term.
Armenian Prime Minister Nikol Pashinyan's party is on course for victory, with Armenian media reporting that the country's Central Election Commission has completed the vote count in the parliamentary elections. An official announcement is still expected.
Armenian authorities arrested six candidates from the pro-Russian Strong Armenia bloc on Saturday, one day before voters were due to take part in parliamentary elections.
Azerbaijan's Foreign Ministry has confirmed the number of casualties its citizens suffered as a result of the 5 June drone attacks on the cargo ships Natra and Zircon in the Sea of Azov. In a statement, it said four Azerbaijani citizens were killed and four others were injured.
The results of Armenia’s parliamentary elections will determine the makeup of the National Assembly and shape the country's political direction for the foreseeable future. But in Armenia, the final result is not decided by vote percentages alone. Here's how it works.
A U.S. doctor who contracted Ebola while on a humanitarian mission in the Democratic Republic of Congo has recovered and been discharged from a hospital in Germany, according to officials.
Protesters in Nanyuki blocked roads and burned tyres after residents challenged a U.S. plan to house Americans exposed to Ebola at a nearby military base.
Global health organisation CEPI will provide around $60 million to Moderna and two other partners to speed up the development of vaccines targeting the Ebola Bundibugyo strain, which is currently driving an outbreak in eastern Democratic Republic of Congo.
The head of the World Health Organization (WHO) has warned that the Ebola outbreak in the Democratic Republic of Congo may be significantly larger than official figures suggest, following a visit to the country where he briefed President Felix Tshisekedi on the ongoing response.
Four nurses have recovered and been discharged after receiving treatment for Ebola in the Democratic Republic of Congo, the World Health Organisation (WHO) said.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment